Chemoprevention of Premalignant and Early Malignant Lesions of the Bladder

Guest Editors

Charles W. Boone
Division of Cancer Prevention and Control
Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

Gary J. Kelloff
Division of Cancer Prevention and Control
Chemoprevention Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

Edward M. Messing
Departments of Surgery and Human Oncology
University of Wisconsin
School of Medicine
Madison, WI

Joel Sheinfeld
Urology Service
Department of Surgery
Memorial Sloan-Kettering Cancer Center
New York, NY
Preface ................................................................................................................................. vi

INTRODUCTORY REMARKS

Development of Chemopreventive Agents for Bladder Cancer
Gary J. Kelloff, Charles W. Boone, Winfred F. Malone, Vernon E. Steele, and Linda A. Doody ............. 1

New Opportunities for Screening and Early Detection of Bladder Cancer
Thomas J. Mason, William P. Walsh, Kathleen Lee, and William Vogler ........................................ 13

Bladder Cancer From a Perspective of 40 Years
Leopold G. Koss .................................................................................................................. 23

PREMALIGNANT AND EARLY MALIGNANT LESIONS OF THE BLADDER

Overview
David G. Bostwick ............................................................................................................ 30

Natural History of Early Bladder Cancer
David G. Bostwick ............................................................................................................ 31

Pathology of Carcinoma In Situ of the Urinary Bladder and Related Lesions
George M. Farrow ............................................................................................................ 39

Papillary Tumors of the Bladder
Myron R. Melamed ........................................................................................................... 44

MARKERS OF EARLY LESIONS

Overview
Joel Sheinfeld ................................................................................................................... 48

Blood Group Antigens in Normal and Neoplastic Urothelium
Joel Sheinfeld, Victor E. Reuter, Alvaro S. Sarkis, and Carlos Cordon-Cardo ................................. 50

Epidermal Growth Factor and Its Receptor: Markers of—and Targets for—Chemoprevention of Bladder Cancer
Edward M. Messing and Catherine A. Reznikoff ...................................................................... 56

Alterations in Antigen Expression in Superficial Bladder Cancer
H. Barton Grossman, Raymond W. Washington, Jr., Thomas E. Carey, and Monica Liebert .......... 63

(continued on next page)
Altered RB Expression Is a Prognostic Clinical Marker Involved in Human Bladder Tumorigenesis
William F. Benedict

DETECTION

Overview
Myron R. Melamed

Cytology
Myron R. Melamed

Chromosome Changes in Early Bladder Neoplasms
Avery A. Sandberg

Evaluation of DNA Flow Cytometry as a Screening Test for Bladder Cancer
Ralph W. deVere White and Arline D. Deitch

Strategies of Chemoprevention Based on Antigenic and Molecular Markers of Early and Premalignant Lesions of the Bladder
Yves Fradet, Louis Lafleur, and Helene LaRue

Intermediate Endpoint Biomarkers for Chemoprevention
George P. Hemstreet III, Jian Yu Rao, Robert E. Hurst, Rebecca Bass Bonner, Philip L. Jones, Abhay M. Vaidya, Yves Fradet, Richard C. Moon, and Gary J. Kelloff

CURRENT THERAPY

Overview
Harry W. Herr

Intravesical BCG: Current Results, Natural History, and Implications for Urothelial Cancer Prevention
Harry W. Herr

Superficial Bladder Cancer: Diagnosis, Surveillance, and Treatment
Mark S. Soloway and Paul E. Perito

Chemotherapy Resistant Transitional Cell Carcinoma as a Target for Chemoprevention
Christopher J. Logothetis

CHEMOPREVENTION

Overview
Richard C. Moon

Chemoprevention of Experimental Bladder Cancer
Richard C. Moon, Carol J. Detrisac, Cathy F. Thomas, and Gary J. Kelloff

Activity of 4-HPR in Superficial Bladder Cancer Using DNA Flow Cytometry as an Intermediate Endpoint

13-cis-Retinoic Acid in Chemoprevention of Superficial Bladder Cancer
George R. Prout, Jr. and Bruce A. Barton

A Prospective Clinical Trial of Difluoromethylornithine (DFMO) in Patients With Resected Superficial Bladder Cancer
Charles L. Loprinzi and Edward M. Messing

Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention
David L. Earnest, Lee J. Hixson, and David S. Alberts
Mechanisms of Chemoprotection by Oltipraz
Thomas Kensler, Peter Styczynski, John Groopman, Kathy Helzlsouër, Thomas Curphey, Yulia Maxuitenko, and B.D. Roebuck

PANEL STATEMENT

Intervention Strategies for Chemoprevention of Bladder Cancer
Joel Sheinfeld, Chairman
Harry W. Herr, Co-Chairman

Author Index

Subject Index

FRONT COVER: Diagram of the surface of the urinary bladder with foci exhibiting different stages of neoplastic progression. Derived from the publications of Dr. Leopold G. Koss (Albert Einstein College of Medicine, Montifiore Medical Center, New York.)

BACK COVER: Electron micrograph of a bladder tumor cell showing intracytoplasmic mucinous material stained by monoclonal antibody M344 revealed by immunogold. Inset: Immunoperoxidase stain of intra-urothelial neoplasia by monoclonal M344 antibody (left) with specificity demonstrated by non-staining of adjacent normal epithelium (right). From the publications of Dr. Yves Fradet (Laval University Cancer Research Center, Quebec, Canada). Contributed by Dr. Charles W. Boone, National Cancer Institute, Chemoprevention Branch (Bethesda, Maryland), in conjunction with the Medical Arts and Photography Branch, Design Section, National Institutes of Health.